Adaptive Biotechnologies Corporation
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation (ADPT) develops an immune medicine platform that harnesses the adaptive immune system to create clinical diagnostics, research tools, and therapeutic insights through high-throughput sequencing of T-cell receptors (TCRs) and B-cell receptors (BCRs); its core products and services include clonoSEQ, an FDA-cleared minimal residual disease (MRD) test for monitoring blood cancers such as multiple myeloma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL); immunoSEQ, a research-use-only platform for immune repertoire profiling used by academic, pharmaceutical, and biotech researchers in biomarker discovery and therapeutic development; T-Detect, a T-cell-based diagnostic platform targeting diseases like Lyme disease, Crohn's disease, multiple sclerosis, and infectious conditions; and immune medicine solutions encompassing pharma services and drug discovery partnerships. Founded in 2009 by brothers Chad Robins and Harlan Robins along with Christopher Carlson, and headquartered in Seattle, Washington, with additional facilities in South San Francisco, California, the company operates primarily in the United States, serving clinical, research, and biopharmaceutical customers focused on oncology, autoimmune disorders, and infectious diseases. Recent developments include the August 2025 termination of its multi-year collaboration with Genentech, a Roche subsidiary, which ended exclusivity obligations in oncology cell therapies and enabled recognition of approximately $41.2 million in non-cash revenue across 2025 while allowing Adaptive Biotechnologies to pivot toward digital TCR-antigen prediction models, new partnering opportunities, and a T-cell depletion program in autoimmunity; ongoing expansion of clonoSEQ adoption with projected 35% growth in fiscal 2025 test volumes; and strategic emphasis on profitability through controlled operating expenses amid $170 million in 2023 revenues and $158 million for the first nine months of 2024.
Company News
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Algert Global LLC Has $2.83 Million Position in Adaptive Biotechnologies Corporation $ADPT
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science
Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT
Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
Adaptive Biotechnologies Q2 Earnings Call Highlights
Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
Caxton Associates LLP Has $500,000 Stake in Adaptive Biotechnologies Corporation $ADPT
D.A. Davidson & CO. Sells 60,300 Shares of Adaptive Biotechnologies Corporation $ADPT
Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?
Amova Asset Management Americas Inc. Sells 352,593 Shares of Adaptive Biotechnologies Corporation $ADPT
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
Adaptive Biotechnologies Business Separation May Unlock Greater Value
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering